Capivasertib + Palbociclib + Fulvestrant for HR+/HER2- Advanced Breast Cancer (CAPItello-292).
Status:
Recruiting
Trial end date:
2027-01-18
Target enrollment:
Participant gender:
Summary
A Phase Ib/III Randomised Study of Capivasertib plus Palbociclib and Fulvestrant versus
Placebo plus Palbociclib and Fulvestrant in Hormone Receptor-Positive and Human Epidermal
Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer
(CAPItello-292).